Search Results

You are looking at 151 - 160 of 384 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center

Harrys A. Torres, Lillian R. Roach, Parag Mahale, Minas P. Economides, Boris Blechacz, Ethan Miller, Roy Borchardt, Anis Rashid, Thein H. Oo, Bhavarth Shukla, Malik Farida, Charles D. Ericsson, Bruno P. Granwehr, and Issam I. Raad

. These patients often have immunosuppression due to systemic chemotherapies and underlying hematologic abnormalities, such as neutropenia, anemia, and thrombocytopenia. Before 2013, antiviral therapy for HCV infections consisted of pegylated interferon

Full access

Chronic Lymphocytic Leukemia: State of the Art and Beyond

John C. Byrd

III trial of the German CLL Study Group comparing fludarabine and cyclophosphamide to FC plus rituximab for previously untreated patients with chronic lymphocytic leukemia: results on survival, progression-free survival, delayed neutropenias and

Full access

NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023

Featured Updates to the NCCN Guidelines

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H. Cheng, Anthony Victor D’Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, George Netto, Julio M. Pow-Sang, Robert Reiter, Mack Roach III, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Ryan A. Berardi, Dorothy A. Shead, and Deborah A. Freedman-Cass

therapies compared with those receiving only ADT and docetaxel. The populations receiving the triplet and doublet therapies experienced similar rates neutropenia, febrile neutropenia, fatigue, and neuropathy, although grade ≥3 adverse events occurred 63% of

Full access

Incorporation of Crizotinib into the NCCN Guidelines

Gregory J. Riely, Jamie E. Chaft, Marc Ladanyi, and Mark G. Kris

using another test), treatment with crizotinib is recommended. The available data support the use of crizotinib in any line of therapy. 4 , 5 Moreover, the relatively well-tolerated nature of crizotinib (severe toxicities such as neutropenia are rare

Full access

Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance

Rupali Roy and Leo I. Gordon

, diffuse alveolar hemorrhage, pulmonary cysts, and pulmonary hypertension. Few data exist regarding late toxicity from rituximab, but late-onset neutropenia (LON) has emerged. Rituximab-associated LON is defined by most investigators as grade III to IV

Full access

Updates in Treatment Strategies for Hodgkin Lymphoma

Ranjana H. Advani

associated with a 5% improvement in modified PFS but also higher rates of febrile neutropenia and neuropathy. The FDA indication approval recommends growth factor support with BV‐AVD. 8 The other issue to consider with these regimens is cost. Because of the

Full access

New Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspective

Dawn Goetz

seen grade 3 or 4 adverse effects are neutropenia, febrile neutropenia, anemia, leukopenia, diarrhea, fatigue, and asthenia. The approximate neutrophil nadir is 12 days, and cabazitaxel carries a black box warning against giving the drug to patients

Full access

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024

Featured Updates to the NCCN Guidelines

Jason Gotlib, Aaron T. Gerds, Peter Abdelmessieh, Haris Ali, Mariana Castells, Andrew Dunbar, Ruth Fein Revell, Tracy I. George, Steven Green, Krishna Gundabolu, Elizabeth Hexner, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Naveen Manchanda, Lucia Masarova, Jori May, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Jeanne Palmer, Ami Patel, Anand A. Patel, Nikolai Podoltsev, Lindsay Rein, Rachel Salit, Moshe Talpaz, Martha Wadleigh, Sarah Wall, Mary Anne Bergman, and Cindy Hochstetler

adverse events were fatigue (9%) and vomiting (5%), while the most common grade ≥3 hematologic adverse events were thrombocytopenia (34%), anemia (30%), and neutropenia (15%). There were 9 cases of intracranial bleeding (ICB) in patients with advanced SM

Full access

Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors

Presented by: Brian T. Hill

low rates of grade ≥3 bleeding (0.9%), contusions (0%), diarrhea (0.3%), and atrial fibrillation (0.3%). Neutropenia, although not infrequent, resulted in relatively low rates of grade ≥3 infection (∼4%), which was “noteworthy” in this heavily

Full access

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Apar Kishor P. Ganti, Billy W. Loo Jr., Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A. D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J. Downey, Martin Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, John C. Grecula, Christine Hann, Wade Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, and Miranda Hughes

biopsies may be indicated in select patients with nucleated red blood cells on peripheral blood smear, neutropenia, or thrombocytopenia suggestive of bone marrow infiltration and with no other evidence of metastatic disease. Bone marrow involvement as the